Possible Treatment Finishes Trial

After announcing the inclusion of Raynaud’s phenomenon in its Phase 1 scleroderma cell therapy program in January, Cytori Therapeutics marked the completion of the 48-week follow-up clinical trial. Scleroderma is a condition that involves the skin and internal organs...